Graves' disease following vaccination against SARS-CoV-2: A systematic review of the reported cases.
COVID-19
Graves’ disease
SARS–CoV–2
thyroiditis
vaccines
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2022
2022
Historique:
received:
06
05
2022
accepted:
23
08
2022
entrez:
14
10
2022
pubmed:
15
10
2022
medline:
18
10
2022
Statut:
epublish
Résumé
The newly developed COVID-19 vaccines have established a safe profile, yet some individuals experience a wide range of adverse events. Recently, thyroid dysfunction, including Graves' disease, has been observed after administration of different COVID-19 vaccines, although causality remains a matter of debate. The aim of this systematic review was to examine the available literature and provide an overview of reported cases of Graves' disease following COVID-19 vaccination. We identified 21 eligible articles which included 57 patients with Graves' disease following COVID-19 vaccination. Fourteen participants were males (25%, 14/57) and 43 (75%, 44/57) were females with a mean age of 44.3 years. The most common presenting symptom was palpitations (63%, 27/43) followed by weight loss (35%, 15/43). The majority of patients received thionamides (47%, 25/53). The clinical status after treatment was provided for 37 patients and it was improved in the majority of them (84%, 31/37). Graves' disease is possibly a condition clinicians may expect to encounter in patients receiving COVID-19 vaccines. While the above adverse event is rare, considering the scarcity of available data in scientific literature, and causality is not yet confirmed, the increased awareness of clinicians and the early recognition of the disorder are important for the optimal management of these patients.
Identifiants
pubmed: 36237182
doi: 10.3389/fendo.2022.938001
pmc: PMC9552880
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
938001Informations de copyright
Copyright © 2022 Triantafyllidis, Giannos, Stathi and Kechagias.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Endocrine. 2022 Jan;75(1):19-21
pubmed: 34727295
Nat Rev Immunol. 2004 Nov;4(11):841-55
pubmed: 15516964
J Endocrinol Invest. 2021 May;44(5):1085-1090
pubmed: 33025553
J Clin Endocrinol Metab. 2021 Jan 23;106(2):e926-e935
pubmed: 33141191
Endocrinology. 2020 Sep 1;161(9):
pubmed: 32652001
J Clin Endocrinol Metab. 2006 Dec;91(12):4873-80
pubmed: 16968788
J Clin Endocrinol Metab. 2021 Aug 18;106(9):2600-2605
pubmed: 34043800
J Autoimmun. 2022 Apr;128:102809
pubmed: 35220164
J Endocrinol Invest. 2022 Jan;45(1):227-228
pubmed: 34342859
Front Neurol. 2022 Apr 04;13:819624
pubmed: 35444608
Rev Endocr Metab Disord. 2021 Dec;22(4):803-815
pubmed: 33241508
J Endocrinol Invest. 2022 May;45(5):1071-1077
pubmed: 35015288
Nature. 2020 Oct;586(7830):594-599
pubmed: 32998157
Endocrine. 2021 Dec;74(3):473-474
pubmed: 34648112
J Endocrinol Invest. 2022 Feb;45(2):465-467
pubmed: 34585363
J Autoimmun. 2021 Dec;125:102738
pubmed: 34653776
Endocrine. 2021 Dec;74(3):470-472
pubmed: 34637073
J Med Virol. 2020 Apr;92(4):401-402
pubmed: 31950516
J Endocrinol Invest. 2020 Oct;43(10):1527-1528
pubmed: 32686042
J Clin Transl Endocrinol Case Rep. 2022 Mar;23:100104
pubmed: 34934633
Travel Med Infect Dis. 2022 May-Jun;47:102314
pubmed: 35307540
ACS Nano. 2021 Sep 28;15(9):14022-14048
pubmed: 34469112
Lancet. 2021 Jul 17;398(10296):213-222
pubmed: 34246358
Nat Med. 2021 Feb;27(2):279-288
pubmed: 33335322
Monaldi Arch Chest Dis. 2022 Jul 27;:
pubmed: 35904103
J Clin Endocrinol Metab. 2022 Apr 19;107(5):e1823-e1834
pubmed: 35100622
J Investig Med High Impact Case Rep. 2021 Jan-Dec;9:23247096211063356
pubmed: 34939881
Nature. 2020 Oct;586(7830):589-593
pubmed: 32785213
J Clin Endocrinol Metab. 2022 May 17;107(6):e2324-e2330
pubmed: 35235663
Nat Med. 2021 Aug;27(8):1319-1321
pubmed: 34253930
JAMA. 2021 Apr 20;325(15):1575
pubmed: 33646285
J Autoimmun. 2021 Sep;123:102710
pubmed: 34332438
J Endocrinol Invest. 2022 Apr;45(4):875-882
pubmed: 34792795
Eur J Case Rep Intern Med. 2021 Sep 02;8(9):002807
pubmed: 34671577
Pharmacoepidemiol Drug Saf. 2007 May;16(5):581-7
pubmed: 17471601
Vaccine. 2019 May 27;37(24):3167-3178
pubmed: 31047671
Nat Hum Behav. 2021 Jul;5(7):947-953
pubmed: 33972767
J Clin Endocrinol Metab. 2022 Mar 24;107(4):e1767-e1768
pubmed: 34752614
Front Immunol. 2021 Jan 19;11:617089
pubmed: 33584709
BMJ Case Rep. 2021 Dec 30;14(12):
pubmed: 34969799
J Hepatol. 2021 Jul;75(1):222-224
pubmed: 33862041
Rev Endocr Metab Disord. 2022 Apr;23(2):137-150
pubmed: 34333732
N Engl J Med. 2020 Dec 17;383(25):2427-2438
pubmed: 32991794
J Med Virol. 2022 Jul;94(7):2917-2918
pubmed: 35233795
Rev Endocr Metab Disord. 2016 Dec;17(4):485-498
pubmed: 27307072
Front Public Health. 2021 Nov 23;9:778964
pubmed: 34888290
Ann Acad Med Singap. 2022 Feb;51(2):127-128
pubmed: 35224612
Vaccines (Basel). 2021 Sep 29;9(10):
pubmed: 34696214
Vaccines (Basel). 2021 Sep 11;9(9):
pubmed: 34579250
J Endocrinol Invest. 2022 Oct;45(10):1835-1863
pubmed: 35347651
J Endocrinol Invest. 2021 May;44(5):891-904
pubmed: 33559848
Front Endocrinol (Lausanne). 2022 Jun 23;13:900964
pubmed: 35813627
Best Pract Res Clin Endocrinol Metab. 2020 Jan;34(1):101412
pubmed: 32265102
J Stroke Cerebrovasc Dis. 2021 Aug;30(8):105906
pubmed: 34111775
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Thyroid. 2021 Sep;31(9):1436-1439
pubmed: 33858208
Front Public Health. 2022 May 31;10:811885
pubmed: 35712290
J Formos Med Assoc. 2022 Sep;121(9):1881-1882
pubmed: 35227587
Endocrine. 2021 Nov;74(2):226-227
pubmed: 34533769